Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Conditions
Interventions
Esketamine 56 mg
Esketamine 84 mg
+1 more
Locations
54
United States
UAB Department of Psychiatry and Behavioral Neurobiology
Birmingham, Alabama, United States
UAB Huntsville Regional Medical Campus
Huntsville, Alabama, United States
Preferred Research Partners
Little Rock, Arkansas, United States
Behavioral Research Specialists LLC
Glendale, California, United States
CalNeuro Research
Los Angeles, California, United States
Pacific Research Partners
Oakland, California, United States
Start Date
November 4, 2020
Primary Completion Date
January 31, 2024
Completion Date
January 31, 2024
Last Updated
April 25, 2025
NCT06396312
NCT02994433
NCT03004521
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions